期刊文献+

口服结核Ag85A-CD226 DNA疫苗在小鼠脾与肠道的表达水平检测 被引量:1

The detection for expression of tuberculosis Ag85A-CD226 DNA in spleen and intestine of mouse after oral inoculation
下载PDF
导出
摘要 目的了解结核Ag85A-CD226 DNA疫苗经灌胃方式接种小鼠后在脾淋巴细胞与肠道的表达情况。方法将构建的pcDNA3.1-Ag85A-CD226、pcDNA3.1-Ag85A和pcDNA3.1-CD226真核表达质粒转化DH5α感受态大肠杆菌,扩增并提取纯化质粒,用脂质体包裹制成DNA疫苗。经灌胃方式将制备的DNA疫苗接种C57BL/6小鼠,设置Ag85A-CD226疫苗组、Ag85A疫苗组、CD226疫苗组、pcDNA3.1质粒组和生理盐水对照组。采用间接免疫荧光法检测Ag85A和CD226在肠道的表达。采用流式细胞术检测脾CD4+T细胞、CD8+T细胞和NK细胞的CD226表达。结果 CD226在Ag85A-CD226疫苗组脾脏CD4+T细胞和NK细胞的表达均明显强于Ag85A疫苗组、CD226疫苗组、pcDNA3.1质粒组和生理盐水对照组,差异具有统计学意义(P<0.01);CD226在Ag85A-CD226疫苗组脾脏CD8+T细胞的表达明显强于Ag85A疫苗组、pcDNA3.1质粒组和生理盐水对照组,差异具有统计学意义(P<0.01),与CD226疫苗组相比虽有所增加,但差异无统计学意义(P>0.05)。CD226在Ag85A-CD226疫苗组小肠派氏淋巴结表达明显强于Ag85A疫苗组、CD226疫苗组、pcDNA3.1质粒组和生理盐水对照组,差异具有统计学意义(P<0.01)。Ag85A只在Ag85A-CD226疫苗组和CD226疫苗组小肠固有层表达,且在Ag85A-CD226疫苗组的表达明显强于CD226疫苗组,差异具有统计学意义(P<0.01)。结论 Ag85A-CD226 DNA疫苗接种后,CD226在脾淋巴细胞和肠道表达增强,Ag85A在肠道表达增强,CD226的表达增加会增强Ag85A在肠道的表达水平。 Objective To detect the expression of tuberculosis Ag85A-CD226 DNA vaccine in splenocyte and intestine of mouse by intragastric administration. Methods E. coli DH5α was transformed by pcDNA3. 1-Ag85A-CD226,pcDNA3. 1-Ag85A or pcDNA3. 1-CD226 plasmid. The liposome encapsulated recombinant DNA vaccine was prepared after extraction and amplification of the recombinant plasmid with endotoxin free kit. The C57BL /6 mice were inoculated by intragastric administration. The mice were randomly divided into Ag85A-CD226 vaccine group,Ag85A vaccine group,CD226 vaccine group,pcDNA3. 1 group and normal control group,respectively. Ag85A or CD226 expression in intestine was detected by immunofluorescence and the expressions of CD226 in CD4+T cells,CD8+T cells and NK cells of spleen were analyzed by flow cytometry. Results The levels of CD226 expression in splenocyte and the small intestine Peyer's patches in Ag85ACD226 vaccine group were higher than those in other groups,P〈0. 01; the expression of Ag85A in the intestinal lamina propria in Ag85A-CD226 vaccine group was higher than that in Ag85A vaccine group,P〈0. 01. Conclusion The expression of CD226 was increased in splenocyte and intestine of mouse,and the increased expression of CD226 could enhance the expression of Ag85A in intestine after inoculation of Ag85A-CD226 DNA vaccination.
出处 《微生物学免疫学进展》 2014年第3期1-5,共5页 Progress In Microbiology and Immunology
基金 国家自然科学基金项目(31270972) 辽宁省科学技术计划项目(2011415052-1)
关键词 AG85A CD226 DNA疫苗 脾脏 小肠固有层 Ag85A CD226 DNA vaccine Spleen Intestinal lamina propria
  • 相关文献

参考文献11

  • 1Ulmer JB,Wahren B,Liu MA. Gene-based vaccines:recent technical and clinical advances[J].Trends in Molecular Medicine,2006,(05):216-222.
  • 2Han KT,Sin JI. DNA vaccines targeting human papillomavirus-as-sociated diseases:progresses in animal and clinical studies[J].Clin Exp Vaccine Res,2013,(02):106-114.
  • 3Bins AD,van den Berg JH,Oosterhuis K. Recent advances towards the clinical application of DNA vaccines[J].NETHERLANDS Journal OF MEDICINE,2013,(03):109-117.
  • 4Wiker HG,Harboe M. The antigen 85 complex:a major secretion product of Mycobacterium tuberculosis[J].Microbiological Reviews,1992,(04):648-661.
  • 5Wang DN,Xu J,Feng YH. Liposomal oral DNA vaccine(mycobacterium DNA)elicits immune response[J].VACCINE,2010,(18):3134-3142.
  • 6Zhang P,Wang JY,Wang DN. Dendritic cell vaccine mod-ified by Ag85A gene enhances anti-tumor immunity against blad-der cancer[J].International Journal of Immunopharmacology,2012,(03):252-260.
  • 7Shibuya A,Campbell D,Hannum C. DNAM-1,a novel ad-hesion molecule involved in the cytolytic function of T lympho-cytes[J].IMMUNITY,1996,(06):573-581.
  • 8Shirakawa J,Shibuya K,Shibuya A. Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1(CD226)[J].INTERNATIONAL IMMUNOLOGY,2005,(03):217-223.
  • 9Seth S,Qiu Q,Danisch S. Intranodal interaction with den-dritic cells dynamically regulates surface expression of the co-stim-ulatory receptor CD226 protein on murine T Cells[J].Journal of Biological Chemistry,2011,(45):39153-39163.
  • 10Mer JB,Wahren B,Liu MA. Gene-based vaccines:recent tech-nical and clinical advances[J].Trends in Molecular Medicine,2006,(05):216-222.

二级参考文献8

  • 1Dhar N, Rao V, Tyaqi AK, et al. Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol (Berl) ,2004, 193(1) :19-25.
  • 2Suttmann H, Jacobsen M, Reiss K, et al. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol, 2004, 172(4 Pt 1):1490-1495.
  • 3Ulmer JB, Liu MA, Montgomery DL, et al. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine, 1997,15 ( 8 ) :792-794.
  • 4Miki K, Nagata T, Tanaka T, et al. Induction of protective ceUular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/ MPF51. Infect Immun,2004, 72(4) :2014-2021.
  • 5Dermeier HM, Rhodes SG, Dean G, et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology, 2004, 112(3) :461-470.
  • 6Jones DH, Partidos CD, Steward MW, et al. Oral delivery of poly ( lactide-co-glycolide ) encapsulated vaccines. Behring Inst Mitt, 1997(98) : 220-228.
  • 7Pascual DW, Powell RJ, Lewis GK, et al. Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of intestine. Behring Inst Mitt, 1997 (98) : 143-152.
  • 8Gronevik E, Mathiesen I, Lomo T. Early events of electroporation- mediated intramuscular DNA vaccination potentiate Thl-directed immune responses. J Gene Med, 2005, 7(9) :1246-1254.

共引文献2

同被引文献265

  • 1张杰(综述),胡良安(审校).妊娠期结核的研究进展[J].医学信息(医学与计算机应用),2014,0(13):605-606. 被引量:3
  • 2刘伟,孙峰,张文宏,张颖.基于吡嗪酰胺药物敏感性改善耐多药结核病治疗结局的研究进展[J].结核病与肺部健康杂志,2014,3(2):77-81. 被引量:5
  • 3耐药结核病综合治疗的回顾与展望[J].结核病与肺部健康杂志,2014,3(3):141-147. 被引量:10
  • 4Nathan C. Drug-resistant tuberculosis: a new shot on goal. Nat Med, 2014, 20(2): 121-123.
  • 5Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. AnnNY Acad Sci , 2014,1323: 56-75.
  • 6Zumla AI, Gillespie SH, Hoelscher M, et al. Newantituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis, 2014, 14 (4): 327-340.
  • 7Gillespie SH, Crook AM, McHugh TO, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med, 2014, 371(17): 1577-1587.
  • 8Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med, 2014, 371(7): 1588-1598.
  • 9j indani A, Harrison TS, Nunn AJ, et al. High-dose rifapen- tine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014. 371(17): 1599160S.
  • 10Warner DF. Mizrahi V. Shortening treatment for tuberculosis+to basics. N Engl J Med, 2014. 371(17): 16421643.

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部